Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents

Felipe A. R. Rodrigues, Igor da S. Bomfim, Bruno C. Cavalcanti, Claudia Pessoa, Raoni S. B. Goncalves, James Lewis Wardell, Solange M. S. V. Wardell, Marcus V. N. de Souza

Research output: Contribution to journalLetter

28 Citations (Scopus)

Abstract

A series of 23 racemic mefloquine-oxazolidine derivatives, 4-[3-(aryl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(trifluoromethyl)quinolines, derived from (R*, S*)-(+/-)-mefloquine and arenealdehydes, have been evaluated for their activity against four cancer cell lines (HCT-8, OVCAR-8, HL-60, and SF-295). Good cytotoxicities have been determined with IC50 values ranging from 0.59 to 4.79g/mL. In general compounds with aryl groups having strong electron-releasing substituents, such as HO and MeO, or electron-rich heteroaryl groups, for example imidazol-2-y-l, are active. However, other factors such as steric effects may play a role. As both the active and non-active conformations of the mefloquine-oxazolidine derivatives are similar, it is concluded that molecular conformations do not play a significant role either. This study is the first to evaluate mefloquine derivatives as antitumor agents. The mefloquine-oxazolidine derivatives are considered to be useful leads for the rational design of new antitumor agents.

Original languageEnglish
Pages (from-to)126-131
Number of pages6
JournalChemical biology & drug design
Volume83
Issue number1
Early online date5 Oct 2013
DOIs
Publication statusPublished - Jan 2014

Keywords

  • anticancer
  • antitumor activity
  • mefloquine
  • oxazolidine
  • in-vitro
  • cell-death
  • autophagy

Cite this

Rodrigues, F. A. R., Bomfim, I. D. S., Cavalcanti, B. C., Pessoa, C., Goncalves, R. S. B., Wardell, J. L., ... de Souza, M. V. N. (2014). Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents. Chemical biology & drug design, 83(1), 126-131. https://doi.org/10.1111/cbdd.12210

Mefloquine-Oxazolidine Derivatives : A New Class of Anticancer Agents. / Rodrigues, Felipe A. R.; Bomfim, Igor da S.; Cavalcanti, Bruno C.; Pessoa, Claudia; Goncalves, Raoni S. B.; Wardell, James Lewis; Wardell, Solange M. S. V.; de Souza, Marcus V. N.

In: Chemical biology & drug design, Vol. 83, No. 1, 01.2014, p. 126-131.

Research output: Contribution to journalLetter

Rodrigues, FAR, Bomfim, IDS, Cavalcanti, BC, Pessoa, C, Goncalves, RSB, Wardell, JL, Wardell, SMSV & de Souza, MVN 2014, 'Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents' Chemical biology & drug design, vol. 83, no. 1, pp. 126-131. https://doi.org/10.1111/cbdd.12210
Rodrigues FAR, Bomfim IDS, Cavalcanti BC, Pessoa C, Goncalves RSB, Wardell JL et al. Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents. Chemical biology & drug design. 2014 Jan;83(1):126-131. https://doi.org/10.1111/cbdd.12210
Rodrigues, Felipe A. R. ; Bomfim, Igor da S. ; Cavalcanti, Bruno C. ; Pessoa, Claudia ; Goncalves, Raoni S. B. ; Wardell, James Lewis ; Wardell, Solange M. S. V. ; de Souza, Marcus V. N. / Mefloquine-Oxazolidine Derivatives : A New Class of Anticancer Agents. In: Chemical biology & drug design. 2014 ; Vol. 83, No. 1. pp. 126-131.
@article{74bd47468cec49a7bd89e7b0393d66a7,
title = "Mefloquine-Oxazolidine Derivatives: A New Class of Anticancer Agents",
abstract = "A series of 23 racemic mefloquine-oxazolidine derivatives, 4-[3-(aryl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(trifluoromethyl)quinolines, derived from (R*, S*)-(+/-)-mefloquine and arenealdehydes, have been evaluated for their activity against four cancer cell lines (HCT-8, OVCAR-8, HL-60, and SF-295). Good cytotoxicities have been determined with IC50 values ranging from 0.59 to 4.79g/mL. In general compounds with aryl groups having strong electron-releasing substituents, such as HO and MeO, or electron-rich heteroaryl groups, for example imidazol-2-y-l, are active. However, other factors such as steric effects may play a role. As both the active and non-active conformations of the mefloquine-oxazolidine derivatives are similar, it is concluded that molecular conformations do not play a significant role either. This study is the first to evaluate mefloquine derivatives as antitumor agents. The mefloquine-oxazolidine derivatives are considered to be useful leads for the rational design of new antitumor agents.",
keywords = "anticancer, antitumor activity, mefloquine, oxazolidine, in-vitro, cell-death, autophagy",
author = "Rodrigues, {Felipe A. R.} and Bomfim, {Igor da S.} and Cavalcanti, {Bruno C.} and Claudia Pessoa and Goncalves, {Raoni S. B.} and Wardell, {James Lewis} and Wardell, {Solange M. S. V.} and {de Souza}, {Marcus V. N.}",
year = "2014",
month = "1",
doi = "10.1111/cbdd.12210",
language = "English",
volume = "83",
pages = "126--131",
journal = "Chemical biology & drug design",
issn = "1747-0277",
publisher = "Blackwell",
number = "1",

}

TY - JOUR

T1 - Mefloquine-Oxazolidine Derivatives

T2 - A New Class of Anticancer Agents

AU - Rodrigues, Felipe A. R.

AU - Bomfim, Igor da S.

AU - Cavalcanti, Bruno C.

AU - Pessoa, Claudia

AU - Goncalves, Raoni S. B.

AU - Wardell, James Lewis

AU - Wardell, Solange M. S. V.

AU - de Souza, Marcus V. N.

PY - 2014/1

Y1 - 2014/1

N2 - A series of 23 racemic mefloquine-oxazolidine derivatives, 4-[3-(aryl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(trifluoromethyl)quinolines, derived from (R*, S*)-(+/-)-mefloquine and arenealdehydes, have been evaluated for their activity against four cancer cell lines (HCT-8, OVCAR-8, HL-60, and SF-295). Good cytotoxicities have been determined with IC50 values ranging from 0.59 to 4.79g/mL. In general compounds with aryl groups having strong electron-releasing substituents, such as HO and MeO, or electron-rich heteroaryl groups, for example imidazol-2-y-l, are active. However, other factors such as steric effects may play a role. As both the active and non-active conformations of the mefloquine-oxazolidine derivatives are similar, it is concluded that molecular conformations do not play a significant role either. This study is the first to evaluate mefloquine derivatives as antitumor agents. The mefloquine-oxazolidine derivatives are considered to be useful leads for the rational design of new antitumor agents.

AB - A series of 23 racemic mefloquine-oxazolidine derivatives, 4-[3-(aryl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(trifluoromethyl)quinolines, derived from (R*, S*)-(+/-)-mefloquine and arenealdehydes, have been evaluated for their activity against four cancer cell lines (HCT-8, OVCAR-8, HL-60, and SF-295). Good cytotoxicities have been determined with IC50 values ranging from 0.59 to 4.79g/mL. In general compounds with aryl groups having strong electron-releasing substituents, such as HO and MeO, or electron-rich heteroaryl groups, for example imidazol-2-y-l, are active. However, other factors such as steric effects may play a role. As both the active and non-active conformations of the mefloquine-oxazolidine derivatives are similar, it is concluded that molecular conformations do not play a significant role either. This study is the first to evaluate mefloquine derivatives as antitumor agents. The mefloquine-oxazolidine derivatives are considered to be useful leads for the rational design of new antitumor agents.

KW - anticancer

KW - antitumor activity

KW - mefloquine

KW - oxazolidine

KW - in-vitro

KW - cell-death

KW - autophagy

U2 - 10.1111/cbdd.12210

DO - 10.1111/cbdd.12210

M3 - Letter

VL - 83

SP - 126

EP - 131

JO - Chemical biology & drug design

JF - Chemical biology & drug design

SN - 1747-0277

IS - 1

ER -